Attenuation of Thrombolysis-induced Increase of Plasminogen Activator Inhibitor-1 by Intravenous Enalaprilat

Summary

We examined the effect of intravenous enalaprilat on the course of PAI-1 plasma levels in 23 patients with acute myocardial infarction undergoing thrombolytic therapy. All patients received 100 mg aspirin, 1000 IU/h heparin, thrombolysis with 100 mg rt-PA within 90 min, and betablockers. Eleven out of 23 patients received 5 mg enalaprilat intravenously prior to thrombolysis. Blood samples for determination of PAI-1 plasma levels were collected on admission, 2, 4, 6, 12, and 24 h after thrombolysis. PAI-1 plasma levels in patients receiving enalaprilat were similar to those of the control patients before thrombolysis (5 ng/ml, 95% confidence interval: 2-10 vs. 7 ng/ml, 95% confidence interval: 2-10; p = 0.5). The PAI-1_AUC was 9 ng/ml/h (95% confidence interval: 5-10) in the enalaprilat group and 19 ng/ml/h (95% confidence interval: 13-26) in the control group (p = 0.0006). The maximum difference was observed 6 h after thrombolysis (enalaprilat: 13 ng/ml, 95% confidence interval: 5-25, control: 42 ng/ml, 95% confidence interval: 18-55; p = 0.003).

Our study clearly demonstrates that application of intravenous enalaprilat prior to thrombolysis attenuates the thrombolysis-related increase of PAI-1. This finding may suggest a possible therapeutic approach to influence the fibrinolytic system in patients with acute myocardial infarction after thrombolysis.

• References

• 1 The GUSTO investigators.. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
• 2 ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4.. a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
• 3 Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis K, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-54.
• 4 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human platelets. Blood 1984; 64: 907-13.
• 5 Levi M, Biemond BJ, Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
• 6 Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 1995; 91: 1175-81.
• 7 Ridker PM, Gaboury CL, Conlin PR, Seely W, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-73.
• 8 The SOLVD Investigators.. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
• 9 Pfeffer MA, Braunwald E, Moyé LA. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 676-7.
• 10 Clemmensen P, Grande P, Saunamäki K, Pedersen F, Svendsen JH, Wagner NB, Granborg J, Madsen JK, Haedersdal C, Wagner GS. Effect of intravenous streptokinase on the relation between initial ST-predicted size and final QRS-estimated size of acute myocardial infarcts. J Am Coll Cardiol 1990; 5: 1252-7.
• 11 Krucoff MW, Croll MA, Pope JE, Granger CB, O’Connor CM, Sigmon KN, Wagner BL, Ryan JA, Lee KL, Kereiakes DJ, Samaha JK, Worley SJ, Ellis SG, Wall TC, Topol EJ, Califf RM. for the TAMI 7 Study Group. Continuous 12-lead ST-segment recovery analysis in the TAMI-7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation 1993; 88: 437-46.
• 12 The TIMI Study Group.. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med 1985; 312: 932-6.
• 13 Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.
• 14 Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-9.
• 15 Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93: 1073-8.
• 16 Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991; 65: 275-9.
• 17 Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis. J Am Coll Cardiol 1991; 18: 1547-54.
• 18 Lucore CL, Fujii S, Sobel BE. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration. Circulation 1989; 79: 1204-13.
• 19 Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, Dagenais GR, Sussex B, Arnold M, Sestier F. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993; 22: 390-8.
• 20 Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation 1990; 82: 1485-93.
• 21 Hamsten A, DeFaire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factors for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
• 22 Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
• 23 Jansson JH, Boman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993; 44: 485-8.